Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination

Drug Testing and Analysis

Volumn 3, Issue 9, 2011, Pages 582-585

  Lin, Joanne C ^a   Jan, Reem K ^a   Kydd, Rob R ^a   Russell, Bruce R ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Benzylpiperazine (BZP); Human; Mood; Party pills; Trifluoromethylphenylpiperazine (TFMPP)

Indexed keywords

DRUG DOSAGE; DRUG PRODUCTS;

BENZYLPIPERAZINE; HUMAN; HUMAN FOLLOWING; METHYLENEDIOXYMETHAMPHETAMINE; MOOD; NEW ZEALAND; ORAL DOSE; PARTY PILL; PIPERAZINE DERIVATIVES; TRIFLUOROMETHYLPHENYLPIPERAZINE;

PELLETIZING;

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; BENZYLPIPERAZINE; PIPERAZINE DERIVATIVE; PLACEBO; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ADDICTION CENTER RESEARCH INVENTORY; ANXIETY; CONFUSION; CONTROLLED STUDY; DEPRESSION; DRUG DEPENDENCE; DYSPHORIA; EUPHORIA; FATIGUE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD DISORDER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROFILE OF MOOD STATES; SELF CONCEPT; SELF REPORT; SEROTONINERGIC SYSTEM; SHORT SURVEY; SOCIAL BEHAVIOR; STIMULATION; VISUAL ANALOG SCALE;

EID: 80053384673     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.285     Document Type: Short Survey

References (39)

1. C. Wilkins, M. Girling, P. Sweetsur, T. Huckle, J. Huakau, Legal Party Pill Use in New Zealand: Prevalence of use, availability, health harms and 'gateway effects' of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP), Centre for Social and Health Outcomes Research and Evaluation (SHORE), Massey University, Auckland 2006.
2. Erowid. Erowid Experience Vaults: Piperazine Reports 2010. Available at: 2010, Accessed 3 October 2010.
3. FDA. U.S. Food and Drug Administration. Available at: 2008, Accessed 30 October 2010.
4. DEA. Drug Enforcement Administration-Drugs and Chemicals of Concern: N-benzylpiperazine. Available at: 2010, Accessed 15 September 2010.
5. U. Antia, H. S. Lee, R. R. Kydd, M. D. Tingle, B. R. Russell, Forensic Sci. Int. 2009, 186, 63.
6. R. F. Staack, G. Fritschi, H. H. Maurer, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 773, 35.
7. H. Campbell, W. Cline, M. Evans, J. Lloyd, A. W. Peck, Eur. J. Clin. Pharmacol. 1973, 6, 170.
8. M. H. Baumann, R. D. Clark, A. G. Budzynski, J. S. Partilla, B. E. Blough, R. B. Rothman, Neuropsychopharmacology 2005, 30, 550.
9. K. Magyar, M. I. Fekete, K. Tekes, T. Torok, Eur. J. Pharmacol. 1986, 130, 219.
10. W. E. Fantegrossi, G. Winger, J. H. Woods, W. L. Woolverton, A. Coop, Drug Alcohol Depen. 2005, 77, 161.
11. L. Herndon, M. E. Pierson, R. A. Glennon, Pharmacol. Biochem. Be. 1992, 43, 739.
12. K. A. Cunningham, B. A. Carroll, J. B. Appel, Psychopharmacology (Berl.) 1986, 89, 134.
13. M. H. Baumann, D. C. Mash, J. K. Staley, Neuroreport 1995, 6, 2150.
14. R. B. Rothman, M. A. Ayestas, C. M. Dersch, M. H. Baumann, Circulation 1999, 100, 869.
15. S. B. Auerbach, N. Kamalakannan, J. J. Rutter, Eur. J. Pharmacol. 1990, 190, 51.
16. F. Miranda, G. Orozco, D. N. Velazquez-Martinez, Behav. Pharmacol. 2002, 13, 303.
17. R. F. Staack, L. D. Paul, D. Springer, T. Kraemer, H. H. Maurer, Biochem. Pharmacol. 2004, 67, 235.
18. U. Antia, M. D. Tingle, B. R. Russell, J. Pharm. Pharmacol. 2009, 61, 877.
19. D. W. Robertson, W. Bloomquist, D. T. Wong, M. L. Cohen, Life Sci. 1992, 50, 599.
20. P. J. Conn, E. Sanders-Bush, J. Pharmacol. Exp. Ther. 1987, 242, 652.
21. P. Schoeffter, D. Hoyer, Naunyn. Schmiedebergs Arch. Pharmacol. 1989, 339, 675.
22. M. S. Grotewiel, H. Chu, E. Sanders-Bush, J. Pharmacol. Exp. Ther. 1994, 271, 1122.
23. I. Cloëz-Tayarani, C. Harel-Dupas, G. Fillion, Fund. Clin. Pharmacol. 1992, 6, 333.
24. E. Meririnne, M. Kajos, A. Kankaanpaa, T. Seppala, Basic Clin. Pharmacol. Toxicol. 2006, 98, 346.
25. R. K. Jan, J. C. Lin, H. Lee, J. L. Sheridan, R. R. Kydd, I. J. Kirk, B. R. Russell, Psychopharmacology (Berl.) 2010, 211, 347.
26. J. C. Lin, N. Bangs, H. Lee, R. R. Kydd, B. R. Russell, Psychopharmacology (Berl.) 2009, 207, 439.
27. J. C. Lin, R. K. Jan, H. Lee, M. A. Jensen, R. R. Kydd, B. R. Russell, Psychopharmacology (Berl.) 2010, 214, 761.
28. R. W. Foltin, M. W. Fischman, Drug Alcohol Depen. 1991, 28, 3.
29. D. M. McNair, J. W. P. Heuchert, E. Shilony, MHC Inc. 2003, 7-8.
30. J. P. Zacny, H. de Wit, Pharmacol. Biochem. Be. 1989, 34, 791.
31. J. Camí, M. Farré, M. Mas, P. N. Roset, S. Poudevida, A. Mas, L. San, R. de la Torre, J. Clin. Psychopharmacol. 2000, 20, 455.
32. L. D. Chait, E. H. Uhlenhuth, C.-E. Johanson, Psychopharmacology 1985, 86, 307.
33. W. R. Martin, J. W. Sloan, J. D. Sapira, D. R. Jasinski, Clin. Pharmacol. Ther. 1971, 12, 245.
34. M. Tancer, C.-E. Johanson, Drug Alcohol Depen. 2003, 72, 33.
35. P. Gee, M. Gilbert, S. Richardson, G. Moore, S. Paterson, P. Graham, Clin. Toxicol. 2008, 46, 802.
36. I. Thompson, G. Williams, B. Caldwell, S. Aldington, S. Dickson, N. Lucas, J. McDowall, M. Weatherall, G. Robinson, R. Beasley, J. Psychopharmacol. 2010, 24, 1299.
37. D. M. Wood, J. Button, S. Lidder, J. Ramsey, D. W. Holt, P. I. Dargan, J. Med. Toxicol. 2008, 4, 254.
38. H. Kalant, CMAJ 2001, 165, 917.
39. A. C. Johnstone, R. A. Lea, K. A. Brennan, S. Schenk, M. A. Kennedy, P. S. Fitzmaurice, J. Psychopharmacol. 2007, 21, 888.